BNT162b2 疫苗在 5 至 11 岁儿童中诱导变异特异性免疫、安全性和 Omicron 突破性感染的风险：一项队列研究,Scientific Reports

当前位置： X-MOL 学术 › Sci. Rep. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

BNT162b2 疫苗在 5 至 11 岁儿童中诱导变异特异性免疫、安全性和 Omicron 突破性感染的风险：一项队列研究
Scientific Reports ( IF 3.8 ) Pub Date : 2023-10-13 , DOI: 10.1038/s41598-023-44565-x
Chee Fu Yung _{1,

2,

3} , Nina Le Bert ₄ , Kai Qian Kam _{1,

2,

3,

5} , Seyed Ehsan Saffari ₆ , Chee Wah Tan ₄ , Yun Yan Mah ₄ , Jinyan Zhang ₄ , Aileen Ying-Yan Yeoh ₄ , Feng Zhu ₄ , Smrithi Hariharaputran ₄ , Chia Yin Chong _{1,

2,

3,

5} , Antonio Bertoletti ₄ , Linfa Wang ₄

Affiliation

关于 BNT162b2 疫苗诱导的变异特异性免疫原性、安全性数据和儿科人群突破性感染动态的信息很少。我们通过对新加坡 5-11 岁健康儿童进行的前瞻性两剂 BNT162b2（10 微克）疫苗接种队列研究来解决这些问题。随访包括定期就诊时的血样、每日疫苗接种症状日记以及 SARS-CoV-2 感染的确认。进行了替代病毒中和试验 (sVNT) 和针对 SARS-CoV-2 变体的尖峰特异性 T 细胞反应。127 名参与者的平均年龄为 8.27 岁 (SD 1.95)，其中 51.2% 为男性。1 剂和 2 剂疫苗接种后针对原始变异的中位 sVNT 水平分别为 61.4% 和 95.1% (p < 0.0001)。针对 Omicron 变体的中和抗体最低，中值为 22.4% (IQR 16.5–30.8)。然而，针对 Omicron 变体的 T 细胞 IFN-γ 细胞因子反应很高，并且在疫苗接种后约 4 个月仍保持这种状态。发烧率从 4%（第 1 剂）显着增加至 11.5%（第 2 剂）。第 2 剂疫苗接种后测量的 sVNT 抑制水平每增加 1%，Omicron 突破性感染的风险就会降低 7.8%。BNT162b2 疫苗是安全的，可诱导良好的 T 细胞反应，但儿童中针对 Omicron 的中和抗体较差。疫苗接种后低中和抗体水平预示着随后的突破性感染。

"点击查看英文标题和摘要"

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study

There is little information on BNT162b2 vaccine-induced variant-specific immunogenicity, safety data and dynamics of breakthrough infections in pediatric populations. We addressed these questions using a prospective two dose BNT162b2 (10 mcg) vaccination cohort study of healthy children 5–11 years in Singapore. Follow up included blood samples at scheduled visits, daily vaccination symptom diary and confirmation of SARS-CoV-2 infection. Surrogate virus neutralization test (sVNT) and spike-specific T cell responses against SARS-CoV-2 variants were performed. The mean age of 127 participants was 8.27 years (SD 1.95) and 51.2% were males. The median sVNT level against original variant after 1 dose and 2 dose vaccination was 61.4% and 95.1% respectively (p < 0.0001). Neutralizing antibodies against the Omicron variant was the lowest, median 22.4% (IQR 16.5–30.8). However, T cell IFN-γ cytokine response against Omicron variant was high and remained so about 4 months after vaccination. Fever rate increased significantly from 4% (dose 1) to 11.5% (dose 2). The risk of Omicron breakthrough infection decreased by 7.8% for every 1% increase in sVNT inhibition level measured after dose 2 vaccination. BNT162b2 vaccines were safe, induced good T cell responses but poor neutralizing antibodies against Omicron in children. Low neutralizing antibody levels post-vaccination was predictive of subsequent breakthrough infection.

更新日期：2023-10-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南